Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.445 HKD | +1.14% | +39.06% | -55.05% |
Sales 2023 | 103M 14.2M 111M 1.14B | Sales 2024 * | 130M 17.94M 140M 1.44B | Capitalization | 175M 24.15M 189M 1.93B |
---|---|---|---|---|---|
Net income 2023 | -379M -52.31M -409M -4.19B | Net income 2024 * | -250M -34.5M -270M -2.76B | EV / Sales 2023 | 3.76 x |
Net cash position 2023 | 4.44M 612K 4.79M 49.03M | Net cash position 2024 * | 510M 70.38M 551M 5.63B | EV / Sales 2024 * | -2.58 x |
P/E ratio 2023 |
-1.03
x | P/E ratio 2024 * |
-0.7
x | Employees | 100 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 90% |
Latest transcript on CANbridge Pharmaceuticals Inc.
1 day | +1.14% | ||
1 week | +39.06% | ||
Current month | +45.90% | ||
1 month | +45.90% | ||
3 months | -25.83% | ||
6 months | -68.44% | ||
Current year | -55.05% |
Managers | Title | Age | Since |
---|---|---|---|
James Xue
CEO | Chief Executive Officer | 55 | 29/01/18 |
Glenn Hassan
DFI | Director of Finance/CFO | 46 | 01/04/19 |
Gerald Cox
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward Hu
BRD | Director/Board Member | 61 | 04/07/22 |
James Geraghty
BRD | Director/Board Member | 70 | 17/07/18 |
Peng Kuan Chan
BRD | Director/Board Member | 61 | 10/06/21 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.445 | +1.14% | 110,000 |
25/04/24 | 0.44 | -6.38% | 196,000 |
24/04/24 | 0.47 | -1.05% | 31,000 |
23/04/24 | 0.475 | +48.44% | 180,000 |
22/04/24 | 0.32 | 0.00% | 0 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-55.05% | 24.15M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |
- Stock Market
- Equities
- 1228 Stock